Impact on costs and quality-adjusted-life-years of treat-to-target treatment strategies initiating methotrexate, or tocilizumab, or their combination in early rheumatoid arthritis. 5 year economic evaluation.

CONCLUSION: Based on our analyses, early initiation of TCZ(+MTX), is not cost-effective compared to MTX initiation in a step-up treat-to-target treatment strategy over 5 years in early RA patients.
PMID: 32739893 [PubMed - as supplied by publisher]

Source: J Rheumatol - July 31, 2020 Category: Rheumatology Authors: Verhoeven MMA, Tekstra J, van Laar JM, Pethö-Schramm A, Borm MEA, Bijlsma JWJ, Jacobs JWG, Lafeber FPJG, Welsing PMJ Tags: J Rheumatol Source Type: research